Aprea Therapeutics, Inc. (APRE) - 10-Q Summary
Business Context and Reporting Period
Company: Aprea Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: Aprea is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. Its primary pipeline consists of two clinical programs: APR-1051 (a WEE1 kinase inhibitor) and ATRN-119 (an ATR inhibitor). The company has no commercial product revenue and relies on grants and equity financing.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Grant Revenue | $1,848 | $354,621 | $282,422 | $1,296,764 |
| Total Operating Expenses | $3,119,236 | $4,451,637 | $10,873,165 | $12,390,374 |
| Net Loss | $(2,972,410) | $(3,783,769) | $(10,143,939) | $(10,063,912) |
| Loss Per Share (Basic/Diluted) | $(0.47) | $(0.64) | $(1.65) | $(1.88) |
| Cash and Cash Equivalents (End of Period) | $13,718,052 (as of Sept 30, 2025) | |||
| Accumulated Deficit | $331,185,811 (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Grant revenue decreased significantly to $1,848 in Q3 2025 from $354,621 in Q3 2024, primarily due to reduced recognition of NIH grant revenue.
- Expense Reduction: Total operating expenses decreased by approximately $1.3 million in Q3 2025 compared to Q3 2024.
- R&D Expenses: Dropped from $2.85 million to $1.64 million. This was driven by a $0.7 million decrease related to the ABOYA-119 clinical trial (ATRN-119) which was voluntarily paused in October 2025, and a $0.4 million decrease related to the initiation phase of the APR-1051 trial.
- G&A Expenses: Decreased slightly by $0.1 million, largely due to lower insurance costs.
- Financing Activity: The company raised approximately $0.8 million in net proceeds during the nine months ended September 30, 2025, through its At-the-Market (ATM) offering program, compared to $14.7 million in the same period in 2024 (which included a significant private placement).
Guidance, Outlook, and Risks
- Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern. The cash balance of approximately $13.7 million is not sufficient to fund operations for at least twelve months from the filing date. The company is actively seeking additional funding.
- Clinical Updates:
- ATRN-119: The company determined the Recommended Phase 2 Dose (RP2D) of 1,100 mg once daily. However, new patient enrollment in the ABOYA-119 monotherapy arms was voluntarily paused in October 2025 to explore combination approaches (e.g., with radiation therapy).
- APR-1051: The Phase 1 dose-escalation study (ACESOT-1051) is ongoing. Open-label safety/efficacy data is anticipated in Q1 2026, with dose-escalation expected to complete in H1 2026.
- Capital Needs: The company expects to incur significant expenses and increasing operating losses for the foreseeable future. It will need substantial additional financing to support continuing operations and clinical development.
- Risk Factors: Key risks include the failure of clinical trials, inability to secure additional capital, regulatory delays, and the impact of the paused enrollment on ATRN-119 development timelines.
Investor Verification Checklist
- Liquidity Runway: Verify the specific timeline for the next financing round and the sufficiency of current cash ($13.7M) to fund operations until then.
- ATRN-119 Strategy: Confirm the status of discussions regarding combination therapy trials following the pause in monotherapy enrollment.
- Grant Dependency: Assess the sustainability of grant revenue given the sharp decline in Q3 2025.
- ATM Capacity: Review the remaining capacity under the $3.0 million ATM agreement and the terms of the March 2024 private placement warrants (Tranche A and B) which could provide up to $18.0 million in future proceeds if triggered.
- Preferred Stock Conversion: Note the conversion of Series A preferred stock to common stock in April 2025 and the remaining balance of preferred shares.